GENE ONLINE|News &
Alchemab and Lilly Partner, Alchemab to Oversee Phase I Trials of ATLX-1282 for ALS
Alchemab Therapeutics and Eli Lilly and Company have entered into an agreement regarding the development of ATLX-1282 for the treatment of amyotrophic lateral sclerosis (ALS). The agreement stipulates that Alchemab will oversee the initial Phase I clinical trials of the drug. Following the Phase I trials, Lilly will take over responsibility for the continued development and eventual commercialization of ATLX-1282. Under the terms of the deal, Alchemab will manage the early clinical testing of ATLX-1282, a novel platform, in patients with ALS. Subsequently, Eli Lilly and Company will handle later-stage development activities, including further clinical trials and, if successful, the process of bringing the drug to market. The companies have not disclosed further details about the parameters of the arrangement.
Newsflash | Powered by GeneOnline AI
Date: May 6, 2025
Author
LATEST
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio
2026-03-13
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
